CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Karuna Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Karuna Therapeutics Inc
99 High Street, 26Th Floor
Phone: (857) 449-2244p:857 449-2244 BOSTON, MA  02110  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 3/18/2024.
This company ceased filing statements with the SEC on 3/28/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline built on the therapeutic potential of its lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. It is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, and for the treatment of psychosis in Alzheimer's disease. Its pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, and pre-clinical muscarinic, TRPC4/5 and target-agnostic compounds for the treatment of psychiatric and neurological conditions.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Christopher J.Coughlin 70 1/3/2023 4/24/2020
President, Chief Executive Officer, Director William J.Meury 55 1/3/2023 1/3/2023
Chief Financial Officer JasonBrown 36 9/29/2023 9/29/2023
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Karuna Securities Corporation
KRTX

General Information
Number of Employees: 339 (As of 2/15/2024)
Outstanding Shares: 38,199,272 (As of 3/12/2024)
Shareholders: 4
Stock Exchange: NASD
Federal Tax Id: 270605902
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024